Author Archives: Natalie Themm
Fluidx Medical Technology’s Innovative Embolic Tumor Treating Device Highlighted in “BEST of GEST” Session at the Global Embolization Oncology Symposium Technologies (“GEST”) Conference
Fluidx Medical’s GPX™ Embolic Device Use for Tumor Treatments Chosen for “BEST of GEST” Embolization Program at the Annual GEST Meeting.
ZIEN Medical Technologies is Expanding
ZIEN Medical Technologies, of Salt Lake City, Utah, announces the integration of Eclipse Design Innovations, of Woods Cross, Utah, as well as the Grand Opening of their new 16,000 sq foot manufacturing/R&D facility to continue to support the Utah Life Sciences industry.
Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelXTM Testing at Primary Care Level
Renalytix Plc announced the publication of results from an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion dollars for a population of 100,000 patients with type 2 diabetes (T2DKD) and chronic kidney disease tested with the Renalytix KidneyIntelX™ testing solution. Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure.
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®
PolarityTE, Inc. today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021.
Perfect Day To Expand Bio Foundry Capabilities in Utah
The Utah Governor’s Office of Economic Opportunity (Go Utah) is pleased to announce that Perfect Day, Inc. is formally expanding its “biology-as-a-service” arm, Scalable Bio Foundry, Inc. (SBF, Inc.) in Utah, bringing up to 64 new high-paying jobs to the state in the next five years.
Javara and Ogden Clinic launch partnership to advance clinical trial access
Javara and Ogden Clinic are proud to announce the launch of a partnership to integrate industry-sponsored clinical trials at the point of care for Ogden Clinic patients.
VIA CAPITAL announces the launch of Tailwind Business Accelerator
Tailwind Business Accelerator is giving $50,000 in cash and services to at least 5 companies in its first cohort, starting November 1. Applications close September 17 for this first cohort.
Genomics 101 by Intermountain Precision Genomics
In a recent article published by Utah Business Magazine, Dr. Lincoln Nadauld, Chief of Precision Health at Intermountain Healthcare, provides an explanation of the genomic world and how precision medicine will be evolving in the future. Intermountain Precision Genomics, a BioUtah member, is located in St. George, Utah and is a world leader in genomics.
Recursion Reports Second Quarter 2021 Financials and Provides Business Updates
Recursion, a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021.
CenExel Clinical Research Acquires Advanced Memory Research Institute
CenExel announces the acquisition of Advanced Memory Research Institute (“CenExel AMRI”), the largest Alzheimer’s Disease clinical research site in the Northeast. CenExel AMRI conducts Phase I through Phase IV studies, primarily in Alzheimer’s Disease, Memory Loss, and Dementia research.
U.S. SKI & SNOWBOARD CHOOSES R-ZERO AS ITS BIOSAFETY PARTNER TO PROTECT ATHLETES AND STAFF
U.S. Ski & Snowboard joins the growing list of professional sports organizations, including NBA and NFL teams, using R-Zero’s tech to reduce health risks from COVID-19 and other airborne and surface pathogens
Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the second quarter ended June 30, 2021.
